Development programs

Innovation is the driving force behind Crucell’s future growth supported by a strong Research & Development (R&D) pipeline.

Our scientists focus on the discovery and development of much-needed solutions for major threats to human health—particularly vaccines and antibodies for the prevention and treatment of infectious diseases. This has resulted in a strong pipeline of investigational products with the potential to revolutionize the fight against diseases such as influenza, rabies, malaria and tuberculosis. 

Crucell’s current pipeline programs comprise:

Vaccines in development:

• Tuberculosis vaccine
• Malaria vaccine
• Ebola and Marburg vaccine
• HIV vaccine
• RSV
• HPV
• Influenza seasonal vaccine

Human antibodies in development:

• Rabies antibody combination
• Influenza antibodies 
• Hepatitis C antibody combination